Pentostatin B-DESC
, I-DESC
Cyclophosphamide I-DESC
and I-DESC
Rituximab I-DESC
Followed I-DESC
by I-DESC
Alemtuzumab I-DESC
for O
Relapsed O
or O
Refractory O
Chronic O
Lymphocytic O
Leukemia O
: O
A O
Phase B-STYPE
2 I-STYPE
Trial I-STYPE
of O
the O
ECOG O
- O
ACRIN O
Cancer O
Research O
Group O
( O
E2903 O
) O
Pentostatin B-DESC
, I-DESC
Cyclophosphamide I-DESC
and I-DESC
Rituximab I-DESC
Followed I-DESC
by I-DESC
Alemtuzumab I-DESC
for O
Relapsed O
or O
Refractory O
Chronic O
Lymphocytic O
Leukemia O
: O
A O
Phase B-STYPE
2 I-STYPE
Trial I-STYPE
of O
the O
ECOG O
- O
ACRIN O
Cancer O
Research O
Group O
( O
E2903 O
) O
2020 O
July O
23 O
. O
2020 O
July O
23 O
. O
M.DSanfordKempin B-AUTH

Dana O
Farber O
Cancer O
Institute O
- O
ECOG O
- O
ACRIN O
Biostatistics O
Center O
Mayo O
Clinic O
Boston O
, O
Rochester O
MA O
, O
MN O
NeilEKay B-AUTH
ElisabethMPaietta I-AUTH
Montefiore O
Medical O
Center O
Bronx O
NY O
JosephJMazza B-AUTH
Marshfield O
Clinic O
Marshfield O
WI O
Mayo O
Clinic O
Rochester O
MN O
RhettPKetterling B-AUTH
OlgaFrankfurt I-AUTH
Northwestern O
University O
Chicago O
IL O
DavidFClaxton B-AUTH

Pentostatin B-DESC
, I-DESC
Cyclophosphamide I-DESC
and I-DESC
Rituximab I-DESC
Followed I-DESC
by I-DESC
Alemtuzumab I-DESC
for O
Relapsed O
or O
Refractory O
Chronic O
Lymphocytic O
Leukemia O
: O
A O
Phase B-STYPE
2 I-STYPE
Trial I-STYPE
of O
the O
ECOG O
- O
ACRIN O
Cancer O
Research O
Group O
( O
E2903 O
) O

Pentostatin B-DESC
, I-DESC
Cyclophosphamide I-DESC
and I-DESC
Rituximab I-DESC
Followed I-DESC
by I-DESC
Alemtuzumab I-DESC
for O
Relapsed O
or O
Refractory O
Chronic O
Lymphocytic O
Leukemia O
: O
A O
Phase B-STYPE
2 I-STYPE
Trial I-STYPE
of O
the O
ECOG O
- O
ACRIN O
Cancer O
Research O
Group O
( O
E2903 O
) O
M.DSanfordKempin B-AUTH

NY O
New O
York O
NY O
NatalieSCallander O
NatalieSCallander B-AUTH
Natalie I-AUTH
S I-AUTH
Callander I-AUTH
GeraldGross I-AUTH
GeraldGross I-AUTH
Gerald I-AUTH
Gross I-AUTH
MartinSTallman I-AUTH
MartinSTallman I-AUTH
Martin I-AUTH
S I-AUTH
Tallman I-AUTH
Pentostatin B-DESC
, I-DESC
Cyclophosphamide I-DESC
and I-DESC
Rituximab I-DESC
Followed I-DESC
by I-DESC
Alemtuzumab I-DESC
for O
Relapsed O
or O
Refractory O
Chronic O
Lymphocytic O
Leukemia O
: O
A O
Phase B-STYPE
2 I-STYPE
Trial I-STYPE
of O
the O
ECOG O
- O
ACRIN O
Cancer O
Research O
Group O
( O
E2903 O
) O
2020 O
July O
23 O
. O
2020 O
July O
23 O
. O
2020 O
July O
23 O
. O
10.1159/000500164 O

Treatment O
for O
relapsed O
/ O
refractory O
( O
R O
/ O
R O
) O
CLL O
, O
prior O
to O
the O
development O
of O
BCR O
signal O
inhibitors O
, O
consisted O
of O
purine O
nucleoside O
based O
therapy O
in O
combination O
with O
cyclophosphamide O
and O
an O
anti O
- O
CD20 O
monoclonal O
antibody O
( O
chemoimmunotherapy O
- O
CIT O
) O
. O
[ O
1][2][3][4 O
] O
The O
combination O
of O
fludarabine O
, O
cyclophosphamide O
and O
rituximab O
( O
FCR O
) O
can O
result O
in O
longterm O
survival O
for O
treatment O
naïve O
, O
fit O
patients O
with O
low O
risk O
genetics O
and O
mutated O
IGVH O
. O
1 O
The O
long O
- O
term O
administration O
of O
B O
- O
cell O
signal O
inhibitors O
alone O
, O
5 O
and O
in O
combination O
6 O
in O
treatment O
naïve O
and O
good O
prognosis O
patients O
, O
has O
resulted O
in O
long O
- O
term O
disease O
-free O
survival O
. O
Ibrutinib O
- O
based O
therapy O
versus O
CIT O
, O
in O
previously O
untreated O
patients O
, O
resulted O
in O
a O
superior O
PFS O
. O
7,8 O
However O
, O
only O
marrow O
ablative O
approaches O
9,10 O
and O
CAR O
- O
T O
cell O
administration O
11 O
have O
resulted O
in O
molecular O
cure O
of O
the O
disease O
. O

Pentostatin O
is O
active O
alone O
and O
in O
combination O
in O
CLL O
. O
[ O
12][13][14][15][16][17][18][19 O
] O
An O
earlier O
phase O
2 O
trial O
tested O
a O
CIT O
regimen O
( O
PCR O
) O
and O
demonstrated O
significant O
efficacy O
in O
previously O
untreated O
elderly O
patients O
with O
CLL O
. O
4 O
Of O
particular O
importance O
was O
the O
ability O
to O
administer O
a O
full O
six O
cycles O
even O
in O
patients O
with O
diminished O
renal O
function O
. O
20 O
Encouraged O
by O
these O
results O
we O
designed O
and O
activated O
a O
phase B-STYPE
2 I-STYPE
trial I-STYPE
, O
E2903 O
, O
for O
R O
/ O
R O
CLL O
that O
incorporated O
6 B-DOSAGE
cycles I-DOSAGE
of O
PCR B-DESC
, O
followed B-DESC
by I-DESC
an I-DESC
anti I-DESC
- I-DESC
CD52 I-DESC
antibody I-DESC
, I-DESC
alemtuzumab I-DESC
, O
as O
consolidation B-DOSAGE
. O
The O
use O
of O
alemtuzumab O
was O
based O
on O
its O
known O
effectiveness O
for O
the O
treatment O
of O
lymphoid O
neoplasms O
, O
including O
CLL O
, O
[ O
21][22][23][24][25][26][27][28][29][30 O
] O
its O
activity O
in O
patients O
with O
17p O
- O
and O
p53 O
mutations O
. O
25 O
and O
activity O
in O
fludarabine O
resistant O
disease O
. O
26 O

This O
was O
a O
phase B-STYPE
2 I-STYPE
trial I-STYPE
for O
R O
/ O
R O
CLL O
conducted O
by O
the O
ECOG O
- O
ACRIN O
NCTN O
Group O
( O
ECOG O
- O
ACRIN O
) O
. O
Eligibility O
criteria O
included O
progressive O
disease O
or O
failure O
to O
achieve O
a O
meaningful O
response O
( O
< O
partial O
response O
( O
PR O
) O
) O
or O
relapse O
after O
prior O
therapy O
( O
including O
fludarabine O
, O
pentostatin O
and O
rituximab O
) O
. O
The O
definition O
of O
progressive O
disease O
was O
based O
upon O
the O
criteria O
of O
the O
National O
Cancer O
Institute O
( O
NCI O
) O
Working O
Group O
. O
31 O
Patient O
requirements O
included O
an O
ECOG O
performance O
status O
of O
0 O
- O
3 O
, O
serum O
creatinine O
< O
2 O
mg O
/ O
dl O
and O
a O
creatinine O
clearance O
> O
30ml O
/ O
min O
. O
Patients O
were O
ineligible O
if O
they O
had O
received O
prior O
alemtuzumab O
. O
Patients O
with O
infections O
were O
not O
eligible O
for O
entry O
onto O
the O
study O
until O
resolution O
of O
the O
infection O
. O
All O
patients O
were O
tested O
for O
hepatitis O
B O
and O
those O
found O
with O
evidence O
of O
viremia O
were O
ineligible O
. O
Patients O
with O
prior O
hepatitis O
B O
infection O
and O
antibodies O
were O
eligible O
. O
Patients O
with O
a O
history O
of O
malignancy O
, O
other O
than O
squamous O
/ O
basal O
cell O
carcinoma O
of O
the O
skin O
or O
in O
situ O
carcinoma O
of O
the O
cervix O
, O
were O
not O
eligible O
unless O
the O
tumor O
was O
curatively O
treated O
at O
least O
two O
years O
prior O
to O
consideration O
for O
the O
protocol O
. O
The O
protocol O
was O
reviewed O
and O
approved O
by O
the O
Institutional O
Review O
Board O
at O
each O
participating O
institution O
. O
All O
patients O
were O
required O
to O
provide O
written O
informed O
consent O
prior O
to O
entry O
, O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
. O

The O
primary O
clinical O
objectives O
of O
the O
trial O
were O
to O
determine O
the O
number O
of O
complete O
remissions O
( O
CR O
) O
, O
nodular O
partial O
remissions O
( O
nPR O
) O
and O
partial O
remissions O
( O
PR O
) O
. O
Secondary O
objectives O
included O
estimation O
of O
the O
overall O
survival O
( O
OS O
) O
and O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
( O
PFS B-METRIC
) O
and O
the O
conversion O
rate O
to O
a O
higher O
response O
category O
after O
alemtuzumab O
. O
Hematologic O
toxicity O
was O
graded O
according O
to O
the O
NCI O
Working O
Group O
guidelines O
31 O
and O
non O
- O
hematologic O
toxicity O
was O
assessed O
according O
to O
the O
NCI O
Common O
Toxicity O
Criteria O
( O
Version O
3.0 O
) O
. O
Clinical O
and O
laboratory O
correlates O
of O
outcome O
were O
analyzed O
, O
including O
the O
Rai O
Staging O
Classification O
, O
32 O
β2-microglobulin O
( O
β2-m O
) O
33,34 O
and O
immunoglobulin O
heavy O
chain O
variable O
region O
( O
IGVH O
) O
mutation O
status O
. O
Elevated O
CD O
38 O
, O
and O
ZAP-70 O
expression O
were O
both O
defined O
as O
> O
20 O
% O
in O
the O
CLL O
population O
. O
35 O
CLL O
FISH O
panel O
status O
36 O
was O
categorized O
utilizing O
the O
following O
hierarchy O
: O
high O
- O
risk O
group O
included O
17p- O
, O
11q- O
, O
6q O
- O
defects O
, O
intermediate O
risk O
patients O
were O
trisomy O
12 O
and O
low O
risk O
patients O
were O
13q O
- O
or O
normal O
by O
FISH O
. O

Patients O
received O
pentostatin O
( O
4mg B-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
IV O
) O
and O
cyclophosphamide O
( O
600mg B-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
IV O
) O
on B-DOSAGE
day I-DOSAGE
one I-DOSAGE
. O
Rituximab O
was O
administered O
for O
the O
first B-DOSAGE
cycle I-DOSAGE
at I-DOSAGE
100 I-DOSAGE
mg I-DOSAGE
on I-DOSAGE
day I-DOSAGE
1 I-DOSAGE
, I-DOSAGE
followed I-DOSAGE
by I-DOSAGE
375 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
on I-DOSAGE
days I-DOSAGE
3 I-DOSAGE
and I-DOSAGE
5 I-DOSAGE
. O
For O
subsequent B-DOSAGE
cycles I-DOSAGE
( I-DOSAGE
2 I-DOSAGE
- I-DOSAGE
6 I-DOSAGE
) I-DOSAGE
rituximab I-DOSAGE
was I-DOSAGE
given I-DOSAGE
at I-DOSAGE
a I-DOSAGE
dose I-DOSAGE
of I-DOSAGE
375 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
on O
the O
same O
day O
as O
the O
pentostatin O
and O
cyclophosphamide O
( O
PCR B-DESC
) O
. O
This O
PCR B-DESC
regimen I-DESC
was O
given B-DOSAGE
on I-DOSAGE
a I-DOSAGE
21-day I-DOSAGE
6-cycle I-DOSAGE
schedule I-DOSAGE
. O
Bactrim B-DESC
DS I-DESC
( O
QOD B-DOSAGE
) O
and O
acyclovir B-DESC
( O
800 B-DOSAGE
mg I-DOSAGE
BID I-DOSAGE
) O
were O
administered B-DOSAGE
during I-DOSAGE
the I-DOSAGE
entire I-DOSAGE
course I-DOSAGE
of O
PCR B-DESC
, O
and O
alemtuzumab B-DESC
administration O
. O
Surveillance O
for O
cytomegalovirus O
( O
CMV O
) O
was O
performed O
at O
each O
cycle O
of O
PCR O
utilizing O
either O
pp65 O
antigenemia O
. O
37 O
or O
CMV O
DNA O
by O
real O
time O
polymerase O
chain O
reaction O
. O
38 O
Discovery O
of O
active O
disease O
resulted O
in O
cessation O
of O
therapy O
and O
treatment O
of O
the O
CMV O
. O
The O
first O
cycle O
of O
PCR B-DESC
was O
to O
be O
administered O
at O
full O
dose O
regardless O
of O
preexisting O
cytopenias O
. O
During B-DOSAGE
cycle I-DOSAGE
one I-DOSAGE
G B-DESC
- I-DESC
CSF I-DESC
( I-DESC
Neupogen I-DESC
) I-DESC
was O
administered B-DOSAGE
SQ I-DOSAGE
daily I-DOSAGE
, I-DOSAGE
beginning I-DOSAGE
two I-DOSAGE
days I-DOSAGE
after I-DOSAGE
treatment I-DOSAGE
for I-DOSAGE
10 I-DOSAGE
consecutive I-DOSAGE
days I-DOSAGE
or O
until O
the O
neutrophil O
count O
was O
greater O
than O
1.0 O
× O
10 O
9 O
/L O
for O
2 O
consecutive O
days O
. O
Pegfilgrastim O
( O
6mg/ O
m O
2 O
every O
three O
weeks O
) O
was O
an O
alternative O
option O
. O
After O
the O
first O
cycle O
the O
decision O
to O
continue O
administration O
of O
growth O
factors O
was O
left O
up O
to O
the O
treating O
physician O
. O

Patients B-DESC
achieving I-DESC
a I-DESC
CR I-DESC
or I-DESC
nPR I-DESC
after I-DESC
PCR I-DESC
were O
then O
observed O
during O
an O
8 O
week O
treatmentfree O
interval O
after O
which O
a O
bone O
marrow O
study O
was O
performed O
for O
pathologic O
confirmation O
of O
response O
. O
Response O
was O
evaluated O
by O
sites O
for O
treatment O
decisions O
and O
reviewed O
centrally O
by O
data O
managers O
. O
After O
confirmation O
of O
response O
, O
alemtuzumab B-DESC
( B-DOSAGE
30 I-DOSAGE
mg I-DOSAGE
SQ I-DOSAGE
) I-DOSAGE
was I-DOSAGE
administered I-DOSAGE
three I-DOSAGE
times I-DOSAGE
a I-DOSAGE
week I-DOSAGE
( I-DOSAGE
TIW I-DOSAGE
) I-DOSAGE
for I-DOSAGE
four I-DOSAGE
weeks I-DOSAGE
. O
The O
subcutaneous O
route O
of O
administration O
was O
utilized O
because O
of O
ease O
of O
administration O
and O
efficacy O
. O
39,40 O
The O
four O
week O
course O
for O
CR O
or O
nPR O
patients O
as O
opposed O
to O
the O
18 O
week O
course O
for O
a O
lesser O
response O
was O
based O
upon O
the O
concept O
that O
robust O
responding O
patients O
would O
need O
less O
intensive O
exposure O
to O
alemtuzumab B-DESC
and O
have O
less O
infectious O
complications O
. O
41 O
Patients O
achieving O
a O
PR O
or O
stable O
disease O
( O
SD O
) O
after O
six O
cycles O
or O
progressive O
disease O
( O
PD O
) O
after O
at O
least O
2 O
cycles O
of O
PCR O
received O
alemtuzumab B-DESC
( O
30 O
mg O
SQ O
TIW O
) O
for O
18 O
weeks O
after O
a O
treatment O
- O
free O
period O
determined O
by O
the O
investigator O
. O

CR O
and O
nPR O
response O
criteria O
, O
determined O
after O
completion O
of O
PCR B-DESC
and O
after O
the O
8 O
week O
hiatus O
noted O
above O
, O
was O
defined O
by O
the O
1996 O
CLL O
Working O
Group O
criteria O
. O
31 O
Computerized O
imaging O
response O
criteria O
were O
not O
used O
to O
evaluate O
the O
responses O
. O
PD O
was O
characterized O
by O
at O
least O
one O
of O
the O
following O
criteria O
: O
> O
50 O
% O
increase O
in O
nodal O
disease O
or O
appearance O
of O
new O
lymph O
nodes O
, O
increase O
in O
the O
size O
of O
liver O
or O
spleen O
, O
> O
50 O
% O
increase O
in O
blood O
lymphocytes O
or O
appearance O
of O
Richter O
's O
syndrome O
. O
Patients O
who O
did O
not O
achieve O
a O
CR O
, O
nPR O
or O
PR O
but O
exhibited O
no O
findings O
consistent O
with O
PD O
were O
considered O
to O
have O
SD O
. O

The O
primary O
endpoint O
was O
the O
response O
rate O
to O
PCR B-DESC
. O
Response O
rates O
and O
confidence O
intervals O
( O
CIs O
) O
were O
calculated O
using O
the O
method O
of O
Atkinson O
and O
Brown O
. O
42 O
The O
distribution O
of O
pretreatment O
characteristics O
between O
responders O
and O
non O
- O
responders O
was O
determined O
using O
the O
Fisher O
's O
exact O
43 O
and O
Wilcoxon O
rank O
sum O
tests O
. O
44 O
A O
multivariate O
logistic O
model O
was O
performed O
on O
the O
response O
rate O
to O
examine O
the O
effects O
of O
potential O
risk O
factors O
. O
OS O
was O
defined O
as O
the O
time O
from O
registration O
until O
death O
from O
any O
cause O
or O
censored O
at O
last O
date O
known O
to O
be O
alive O
. O
PFS B-METRIC
was O
defined O
as O
the O
time O
from O
registration O
to O
disease O
progression O
or O
any O
cause O
of O
death O
in O
the O
absence O
of O
progression O
. O
OS O
and O
PFS B-METRIC
were O
estimated O
using O
the O
Kaplan O
- O
Meier O
method O
. O
45 O
Log O
rank O
tests O
were O
used O
to O
examine O
the O
effects O
of O
risk O
factors O
on O
OS O
and O
PFS B-METRIC
. O
Univariate O
and O
multivariate O
Cox O
models O
were O
performed O
on O
OS O
and O
PFS B-METRIC
to O
examine O
the O
potential O
risk O
factors O
. O
Factors O
with O
P<0.15 O
in O
the O
univariate O
model O
were O
included O
in O
the O
multivariate O
model O
as O
covariates O
. O
If O
> O
10 O
% O
of O
patients O
had O
a O
missing O
value O
for O
a O
particular O
covariate O
an O
indicator O
for O
whether O
or O
not O
the O
covariate O
was O
missing O
was O
indicated O
in O
the O
multivariate O
mode O
. O
Landmark O
analysis O
at O
6 O
months O
was O
done O
when O
patients O
had O
scheduled O
PCR B-DESC
treatment O
cycles O
completed O
and O
was O
utilized O
to O
compare O
the O
overall O
survival O
between O
responders O
and O
non O
- O
responders O
. O
All O
p O
- O
values O
reported O
are O
for O
two O
- O
sided O
significance O
tests O
with O
p O
- O
values O
under O
0.05 O
considered O
significant O
. O

A O
total O
of O
102 O
patients O
were O
enrolled O
in O
E2903 O
beginning O
in O
December O
2004 O
( O
Figure O
1 O
) O
. O
The O
study O
was O
closed O
to O
accrual O
in O
May O
2013 O
. O
Two O
patients O
did O
not O
begin O
assigned O
therapy O
( O
declined O
to O
receive O
therapy O
; O
received O
alternative O
therapy O
) O
and O
four O
patients O
were O
ineligible O
for O
response O
because O
of O
violations O
of O
the O
inclusion O
criteria O
. O
Efficacy O
analysis O
included O
96 O
patients O
and O
safety O
analysis O
( O
toxicity O
) O
included O
all O
100 O
patients O
who O
started O
treatment O
. O
The O
baseline O
clinical O
, O
laboratory O
and O
prognostic O
factor O
characteristics O
are O
shown O
in O
Table O
1 O
. O
The O
median O
age O
was O
64 O
years O
( O
range O
38 O
- O
81 O
years O
) O
and O
the O
majority O
of O
patients O
were O
male O
( O
79 O
% O
) O
. O
An O
ECOG O
performance O
status O
of O
0 O
- O
1 O
was O
present O
in O
96 O
% O
of O
patients O
and O
57 O
% O
of O
patients O
were O
Rai O
stages O
III O
- O
IV O
. O
The O
number O
of O
patients O
having O
received O
≥ O
2 O
prior O
treatments O
was O
56 O
% O
. O
Among O
the O
91 O
patients O
with O
serum O
β2-m O
information O
, O
56(58 O
% O
) O
had O
a O
level O
≤3.5 O
mgs O
/ O
ml O
. O
Of O
the O
66 O
patients O
with O
ZAP-70 O
and O
CD38 O
studies O
, O
45 O
% O
and O
51 O
% O
, O
respectively O
, O
were O
positive O
based O
upon O
previous O
flow O
threshold O
determinations O
. O
33 O
Unmutated O
IGHV O
status O
was O
found O
in O
68 O
% O
of O
available O
patient O
material O
. O
Pre O
- O
therapy O
FISH O
data O
was O
available O
in O
78 O
patients O
and O
demonstrated O
high O
- O
risk O
defects O
in O
47 O
% O
( O
17p- O
, O
11q- O
, O
6q O
) O
, O
intermediate O
risk O
in O
15 O
% O
( O
trisomy O
12 O
) O
and O
low O
risk O
in O
32 O
% O
( O
13q- O
, O
normal O
) O
. O

Patients O
with O
a O
lower O
( O
0 O
- O
2 O
) O
Rai O
stage O
( O
p=0.04 O
) O
, O
fewer O
prior O
regimens(<2 O
) O
( O
p=0.02 O
) O
, O
hemoglobin O
> O
10g O
/ O
dl O
( O
p= O
0.03 O
) O
, O
β2-m O
≤ O
3.5 O
( O
p=0.03 O
) O
, O
and O
CD O
38 O
negativity O
( O
p=0.01 O
) O
were O
more O
likely O
to O
respond O
to O
PCR O
. O
In O
a O
multivariate O
logistic O
model O
only O
CD O
38 O
< O
20 O
% O
was O
significantly O
associated O
with O
a O
PCR B-DESC
response O
( O
p=0.01 O
) O
. O
The O
response O
rates O
are O
81 O
% O
and O
50 O
% O
for O
patients O
with O
CD38 O
negative O
and O
positive O
status O
respectively O
. O
Although O
baseline O
IGHV O
status O
and O
FISH O
studies O
were O
largely O
unfavorable O
, O
neither O
was O
associated O
with O
response O
( O
IGHV O
mutation O
: O
p=0.36 O
; O
FISH O
risk O
: O
p=0.61 O
) O

The O
median O
OS O
was O
27 O
months O
( O
90 O
% O
CI O
: O
20 O
- O
42 O
) O
( O
Figure O
2A O
) O
and O
the O
median B-METRIC
PFS I-METRIC
was O
12 B-RESULTS
months I-RESULTS
( I-RESULTS
90 I-RESULTS
% I-RESULTS
CI I-RESULTS
: I-RESULTS
9 I-RESULTS
- I-RESULTS
14 I-RESULTS
) I-RESULTS
( O
Figure O
2B O
) O
. O
There O
was O
no O
significant O
difference O
in O
OS O
between O
CR O
/ O
nPR O
responders O
( O
21 O
months O
) O
and O
lesser O
responders O
( O
29.0 O
months)(p=0.74 O
) O
. O

In O
a O
multivariate O
model O
of O
OS O
, O
both O
β2-m O
≤3.5 O
mg O
/ O
L O
( O
p=0.01 O
) O
and O
low O
FISH O
risk O
( O
p=.02 O
) O
were O
significant O
factors O
for O
OS O
. O
If O
β2-m O
was O
≤ O
3.5 O
mg O
the O
median O
survival O
was O
56 O
months O
versus O
19 O
months O
if O
the O
β2-m O
was O
> O
3.5 O
mg O
/ O
L O
( O
Figure O
3A O
) O
. O
For O
low O
- O
risk O
FISH O
the O
median O
survival O
was O
47.2 O
months O
versus O
15.9 O
months O
for O
high O
- O
risk O
FISH O
( O
Figure3B O
) O
. O
In O
a O
multivariate O
model O
, O
β2-m(≤ O
3.5mg O
/ O
L O
) O
, O
IGHV O
mutation O
status O
, O
and O
lower O
FISH O
risk O
were O
not O
significantly O
associated O
with O
PFS B-METRIC
( B-RESULTS
p=.08 I-RESULTS
) I-RESULTS
. O

Treatment O
- O
related O
toxicities O
during O
PCR B-DESC
and O
alemtuzumab B-DESC
were O
those O
expected O
in O
patients O
with O
R O
/ O
R O
CLL O
receiving O
CIT O
( O
Table O
2 O
) O
. O
Anemia O
, O
thrombocytopenia O
and O
neutropenia O
were O
observed O
in O
16 O
% O
, O
34 O
% O
and O
60 O
% O
, O
respectively O
, O
during O
PCR B-DESC
treatment I-DESC
. O
The O
worst O
- O
degree O
of O
non O
- O
hematologic O
treatment O
- O
related O
toxicities O
during O
PCR B-DESC
treatment I-DESC
were O
grades O
3 O
- O
4 O
in O
47 O
patients O
( O
47 O
% O
) O
and O
grade O
5 O
in O
5 O
patients O
( O
5 O
% O
) O
. O
These O
included O
fatigue O
( O
9 O
% O
) O
, O
nausea O
( O
8 O
% O
) O
and O
vomiting O
( O
7 O
% O
) O
. O
Metabolic O
abnormalities O
were O
observed O
in O
18(18 O
% O
) O
patients O
but O
all O
were O
less O
than O
grade O
4 O
. O
Tumor O
- O
lysis O
syndrome O
was O
documented O
in O
six O
patients O
, O
all O
grade O
3 O
. O
Febrile O
neutropenia O
occurred O
in O
10 O
patients O
( O
10 O
% O
) O
. O
Most O
infections O
, O
either O
presumed O
or O
proven O
, O
were O
grades O
1 O
- O
3 O
. O
These O
included O
respiratory O
tract O
, O
urinary O
tract O
, O
skin O
and O
ocular O
site O
infections O
. O
Colitis O
, O
unrelated O
to O
CMV O
, O
occurred O
in O
two O
patients O
( O
C. O
difficile O
, O
unknown O
) O
. O
Septicemia O
was O
documented O
in O
2 O
patients O
, O
one O
of O
whom O
died O
. O
Pneumonia O
, O
attributable O
to O
CMV O
occurred O
in O
2 O
patients O
. O
There O
were O
5 O
treatment O
- O
related O
deaths O
during O
the O
PCR B-DESC
therapy I-DESC
including O
multiorgan O
failure O
( O
1 O
) O
, O
ARDS O
, O
non O
- O
CMV O
( O
1 O
) O
, O
infection O
( O
1 O
) O
, O
pneumonitis O
( O
2 O
) O
. O

During O
the O
alemtuzumab B-DESC
treatment I-DESC
arms I-DESC
, O
pain O
at O
the O
injection O
site O
, O
fever O
, O
and O
myalgias O
were O
grades O
I O
or O
2 O
. O
One O
patient O
with O
a O
grade O
4 O
local O
injection O
site O
reaction O
was O
removed O
from O
study O
after O
2 O
doses O
of O
alemtuzumab B-DESC
. O
Myelosuppression O
was O
as O
common O
as O
during O
the O
PCR O
. O
One O
patient O
developed O
CMV O
positive O
serology O
during O
the O
4-week O
alemtuzumab B-DESC
treatment O
and O
two O
patients O
in O
subsequent O
follow O
- O
up O
. O
Two O
patients O
developed O
CMV O
positive O
serology O
during O
the O
18-week O
alemtuzumab B-DESC
treatment I-DESC
, O
two O
of O
whom O
developed O
pneumonia O
. O

The O
autoimmune O
disorders O
found O
in O
this O
study O
are O
those O
previously O
described O
in O
CLL O
patients O
. O
46 O
Although O
autoimmune O
cytopenia O
occurs O
in O
CLL O
, O
occasionally O
related O
to O
purine O
nucleoside O
or O
alemtuzumab O
administration O
, O
[ O
47][48][49 O
] O
there O
were O
no O
cases O
in O
the O
present O
study O
. O
Second O
malignancy O
in O
patients O
with O
CLL O
has O
been O
well O
- O
documented O
. O
[ O
50][51][52][53 O
] O
The O
spectrum O
of O
second O
malignancies O
documented O
in O
this O
trial O
included O
non O
- O
Hodgkin O
lymphoma O
( O
NHL O
) O
( O
5 O
) O
, O
including O
three O
cases O
of O
Richter O
's O
syndrome O
, O
myelodysplastic O
syndrome O
. O
( O
2 O
) O
, O
non O
- O
melanoma O
skin O
tumors O
( O
7 O
) O
, O
breast O
cancer O
( O
1 O
) O
, O
colorectal O
cancer O
( O
1 O
) O
, O
esophageal O
cancer O
( O
1 O
) O
, O
bladder O
cancer O
( O
1 O
) O
, O
and O
metastatic O
undifferentiated O
adenocarcinoma O
( O
1 O
) O
. O
No O
cases O
of O
melanoma O
were O
observed O
. O
54 O